Resources

The right time to consider transfer pricing and how early stage biotechs can take a more pragmatic approach

Chris Molloy on investment for BIA members; TIME’s Best Inventions; MHRA 2030 Strategy; Rare disease medicines review; Party conferences; TechBio; and BIA's AGM

PIR International recently partnered with CellCentric in appointing Paolo Pucci as Independent Non-Executive Director.

IMU Biosciences has announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data.

Microbiotica announces the first close of a £36 million ($48 million) Series C financing.

Recursion announced a $200 million underwritten offering of common stock with leading healthcare and institutional investors.

Graham Hewson has been appointed as Chief Business Officer of the Royal Veterinary College (RVC) and Chief Executive Officer of the London Bioscience Innovation Centre (LBIC).

OMass Therapeutics announced an oversubscribed $310 million (£230 million) Series C financing round.

Brainomix, today announced a new partnership with the Pulmonary Fibrosis Foundation (PFF) to bring the voices of patients and caregivers into exploring how AI-powered imaging could support the care of people living with pulmonary fibrosis (PF) and other fibrotic interstitial lung diseases (ILD).

Engitix announced the appointment of Ryan Richardson to its Board of Directors as Independent Non-Executive Director (NED).

Discovery Park welcomed two climate-tech companies to its innovation campus

Chris Molloy on investment in dementia; AI in healthcare; TechBio; BioJapan; bioProcessUK; Green, Conservative and Labour conferences; and BIA Board elections

o2h Technology Launches Tech Kickstarter 5.0 to Support Early-Stage Startups

Alliance of CGT Manufacturing Partners (ACGMP) founding members aim to help cell and gene therapy developers find manufacturing partners across regions and modalities, with a shared focus on global patient access.

ELRIG announced the keynote speakers for Protein Sciences in Drug Discovery 2026.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

 What future-proofing means in regulated scientific environments

Coulter Partners successfully led a search assignment for Valo Therapeutics Group to place Carlos de Sousa, M.D., MBA, as Chief Executive Officer.